BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, January 27, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 27, 2021

View Archived Issues

Tetracyclines may help in mitochondrial disease

Read More

BioVaxys announces advances in its vaccine platforms

Read More

TLR2/6 activation using INNA-051 shows promise as prophylactic strategy against COVID-19

Read More

Model reveals key role of LGI1-ADAM22-MAGUK complex in transsynaptic nanoarchitecture

Read More

Enrollment begins in first-in-human trial of BI-1808 in solid tumors and CTCL

Read More

Vir releases initial phase I data for its HBV-neutralizing monoclonal antibody, VIR-3434

Read More

Keytruda approved in Europe as first-line treatment of metastatic MSI-H or dMMR colorectal cancer

Read More

First patients dosed in phase II study of GS-248 in systemic sclerosis

Read More

Incyte divulges FGFR-3 inhibitors

Read More

Medshine Discovery patents new PORCN inhibitors

Read More

Positive interim data from phase III prevention trial of REGEN-COV

Read More

Boragen presents new tyrosine kinase inhibitors

Read More

Qilu Regor Therapeutics patent details MAP4K1 inhibitors

Read More

New CDK inhibitors patented by Nuvation Bio

Read More

Microbial tyrosine metabolism protects against asthma

Read More

BLAZE-1 study of bamlanivimab plus etesevimab meets primary endpoint in high-risk COVID-19

Read More

OS Therapies receives approval for its phase IIb study of OST-HER2 in osteosarcoma

Read More

PARP inhibitor stenoparib shows activity against SARS-CoV-2

Read More

Rhythm presents positive clinical data and development update for setmelanotide

Read More

FDA approves phase II/III HIBISCUS trial of traumakine in patients with COVID-19

Read More

FDA allows Cardif Oncology to proceed with phase II trial of onvansertib in PDAC

Read More

Sorrento reports preliminary phase Ib results on COVI-MSC for COVID-19

Read More

Primary endpoint met in ACTIVATE-T trial of mitapivat in transfused patients with PK deficiency

Read More

Syndesi reports phase I data on SV2A modulator SDI-118

Read More

DPP-4 inhibitor sitagliptin prevents incidence of GvHD after allogeneic HSCT in AML

Read More

BriaCell reports data from monotherapy and combination therapy studies of Bria-IMT

Read More

FDA clears IND for anti-4-1BB therapeutic monoclonal antibody EU-101

Read More

NIAID reports phase IIb results on VRC-01 for HIV prevention

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 26, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 23, 2026.
  • DNA mutations or genetic disorder concept art

    Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

    BioWorld Science

    Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...

  • Illustration of human body surrounded by DNA, cell and drug icons

    Cell/gene therapy sector now sustainable; China competition mounting

    BioWorld
    There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
  • Dice spelling out D-E-A-L-?, yes, no

    Muted and missing M&As: JPM deals absent in 2026

    BioWorld
    For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing